📚 Lecture Overview
This lecture covers the pathophysiology, classification, diagnosis, and management of polycythemia, with a primary focus on the myeloproliferative neoplasm Polycythemia Vera (PV). It contrasts primary bone marrow disorders with secondary causes of erythrocytosis, outlining the clinical criteria and risk-stratified treatment pathways essential for clinical practice.
🎯 Key Concepts & Definitions
- Polycythemia: A clinical condition characterized by an abnormal increase in the total number of red blood cells (RBCs).
- Polycythemia Vera (PV): A primary myeloproliferative neoplasm originating in the bone marrow, characterized by autonomous overproduction of RBCs.
- Secondary Polycythemia: An elevation in RBC count driven by external factors, such as hypoxia, erythropoietin (EPO)-producing tumors, or exogenous drug administration, rather than a primary bone marrow defect.
- Panmyelosis: A bone marrow biopsy finding showing hypercellularity with the proliferation of all three major myeloid cell lines (erythroid, granulocytic, and megakaryocytic).
- Aquagenic Pruritus: Intense, severe itching triggered by contact with warm water (e.g., after a bath) without a visible skin rash, highly characteristic of PV.
- Erythromelalgia: A painful, burning sensation accompanied by redness and warmth in the extremities (fingers and toes) due to microvascular occlusion.
📖 Main Content
1. Classification and Etiology of Polycythemia
Polycythemia is broadly divided into primary and secondary forms based on the origin of the cellular proliferation.
Primary Polycythemia (Polycythemia Vera)
- The underlying defect resides within the bone marrow itself.
- Leads to autonomous production of RBCs independent of physiological regulatory mechanisms.
Secondary Polycythemia
The bone marrow is structurally normal, but RBC production is driven by external factors:
- Hypoxia-Induced: Any condition causing low systemic oxygen levels triggers physiological EPO production.
- Lung Diseases: Chronic Obstructive Pulmonary Disease (COPD), Obstructive Sleep Apnea.
- Cardiology: Cyanotic Heart Disease.
- Environmental: Living at high altitudes.
- Malignancy (Inappropriate EPO Production): Certain tumors secrete ectopic erythropoietin.
- Examples: Renal Cell Carcinoma, Leiomyosarcoma.
- Exogenous Substances:
- Direct EPO administration (e.g., blood doping or excessive clinical dosing).
- Androgens (which stimulate natural EPO production when taken in incorrect doses).
2. WHO Diagnostic Criteria for Polycythemia Vera
To diagnose Polycythemia Vera, secondary causes must first be excluded. Diagnosis requires meeting either all 3 Major Criteria OR the first 2 Major Criteria plus the 1 Minor Criterion.
| Criterion Type | Parameter | Specific Details |
|---|---|---|
| Major Criterion 1 | Elevated Hemoglobin or Hematocrit | Hemoglobin > 16.5 g/dL in males or > 16.0 g/dL in females. |
| Major Criterion 2 | Bone Marrow Biopsy Findings | Must show panmyelosis (hypercellularity with erythroid, granulocytic, and megakaryocytic proliferation). Note: A biopsy is required, not an aspirate. |
| Major Criterion 3 | JAK2 Mutation | Positive for the JAK2 mutation (present in >95% of PV cases). |
| Minor Criterion | Subnormal Serum EPO | Serum erythropoietin level is below the normal reference range. |
3. Clinical Presentation and Pathophysiology
The clinical manifestations of PV stem from hyperviscosity (thickened blood) and increased cell turnover.
Increased RBCs ➔ Hyperviscosity ➔ Poor Blood Flow ➔ Reduced Tissue Perfusion
- Central Nervous System (CNS): Headache and dizziness due to sluggish cerebral blood flow.
- Ophthalmologic: Blurring of vision.
- Pulmonary: Dyspnea (shortness of breath) and chest pain.
- Dermatologic:
- Aquagenic Pruritus: Severe itching after contact with warm water without a rash, caused by vasodilation and histamine release from increased basophils (basophilia).
- Erythromelalgia: Burning, redness, and pain in the fingers and toes due to microvascular congestion.
- Splenomegaly (Occurs in ~50% of patients):
- Pain: Left hypochondrium pain caused by the sheer size of the spleen, stretching of the splenic capsule, or splenic infarction.
- Compressive Symptoms: Early satiety (feeling full quickly) due to the enlarged spleen pressing against the stomach.
Key Complications
- Thrombosis: High risk of arterial or venous blood clots due to hyperviscosity and thrombocytosis.
- Peptic Ulcer Disease: Histamine released from basophils increases gastric acid secretion.
- Hyperuricemia: High cell turnover releases purines, which metabolize into uric acid, causing gout and kidney stones.
4. Risk Stratification and Management
Treatment is determined by risk stratification to prevent thrombotic complications while managing cell counts.
General & Supportive Care (All Patients)
- Aggressive Hydration: Crucial to decrease blood viscosity.
- Low-dose Aspirin: Prophylaxis to prevent thrombosis.
- Allopurinol: To treat or prevent hyperuricemia (gout/kidney stones).
Risk Stratification Table
| Risk Category | Definition | Treatment Strategy |
|---|---|---|
| Low-Risk | Age < 60 years AND no history of thrombosis | 1. Prophylactic low-dose Aspirin 2. Phlebotomy (venesection) to control hematocrit |
| High-Risk | Age ≥ 60 years OR history of thrombosis | 1. Prophylactic low-dose Aspirin 2. Phlebotomy 3. Cytoreductive Therapy |
Therapeutic Modalities
- Phlebotomy (Venesection): Regular removal of blood (e.g., 500 mL) to maintain target hematocrit. The removed blood is discarded and never transfused because the cells are abnormal.
- Cytoreductive Therapy:
- Hydroxyurea: Suppresses bone marrow production. Requires close CBC monitoring due to the risk of inducing pancytopenia.
- JAK2 Inhibitors (e.g., Ruxolitinib / Jakafi): Targets the underlying mutation in JAK2-positive patients.
- Bone Marrow Transplant: The only potentially curative treatment, though not widely available or commonly performed for this condition.
📊 Visual Learning
Diagram 1: Diagnostic Decision Tree
Diagram 2: Classification of Polycythemia
Diagram 3: Treatment Selection Algorithm
💡 Important Points to Remember
- Biopsy vs. Aspirate: A bone marrow biopsy is mandatory for diagnosing PV because it preserves the architectural layout necessary to identify panmyelosis; an aspirate is insufficient.
- Blood Donation Rule: Blood removed from PV patients during therapeutic phlebotomy is discarded, not donated, due to its hyperviscosity and abnormal cellular components.
- The Histamine Connection: Basophilia in PV leads to high histamine levels, explaining both aquagenic pruritus and the increased risk of peptic ulcer disease.
- Allopurinol Rationale: Any condition with high cell turnover (like PV, leukemia, or myelofibrosis) releases excess purines, making Allopurinol necessary to prevent gouty arthritis and renal calculi.
- JAK2 Prevalence: While the JAK2 mutation is present in >95% of PV cases, its absence does not completely rule out the disease if other criteria are met.
- Memory Aid for Secondary Causes: Think of secondary polycythemia as "H.E.L.P.":
- Hypoxia (COPD, high altitude, sleep apnea)
- Exogenous drugs (Androgens, EPO)
- Lung/heart diseases (Cyanotic heart disease)
- Producing tumors (Renal cell carcinoma, Leiomyosarcoma)
⚠️ Common Exam Questions & Traps
How Examiners Try to Trick Students:
- The Bone Marrow Trap: A question might state that "bone marrow aspirate shows panmyelosis" to satisfy a major criterion. This is false. The WHO guidelines strictly require a bone marrow biopsy.
- The Phlebotomy Misconception: Examiners may ask if a PV patient's phlebotomized blood can be utilized for blood bank donations. Remember: It must be discarded.
- The EPO Level Confusion: In secondary polycythemia (especially hypoxia-induced), EPO levels are elevated. In primary polycythemia (PV), EPO levels are subnormal (low) due to negative feedback. Examiners love to swap these.
- Age Cutoff Error: Students often confuse the risk stratification age limit. The cutoff is 60 years (Low risk is $<60$ and no thrombosis; High risk is $≥ 60$ OR history of thrombosis).
📝 Quick Review Checklist
I can state the exact hemoglobin cutoffs for diagnosing PV in both males ($>16.5$ g/dL) and females ($>16.0$ g/dL).
I can list the 3 Major and 1 Minor WHO diagnostic criteria for Polycythemia Vera.
I understand why a bone marrow biopsy is preferred over an aspirate in PV.
I can explain the physiological mechanism behind aquagenic pruritus and erythromelalgia.
I can identify the secondary causes of polycythemia (hypoxia, tumors, exogenous drugs).
I know how to risk-stratify a PV patient based on age and thrombotic history.
I can name the primary cytoreductive agent used in high-risk PV (Hydroxyurea) and its main side effect (pancytopenia).
I can explain why Allopurinol and Aspirin are routinely prescribed to PV patients.